Related Experiment Video

Updated: Jun 9, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

[New oral anticoagulants: better than vitamin K antagonists?]

H Völler1, S Alban, D Westermann

  • 1FESC, Klinik am See, Rehabilitationszentrum für Innere Medizin, Seebad 84, Rüdersdorf, Germany. heinz.voeller@klinikamsee.com

Der Internist
|September 3, 2010
PubMed

Insights

New anticoagulants like dabigatran etexilate, rivaroxaban, and apixaban show effectiveness comparable or superior to vitamin K antagonists for venous thrombosis and atrial fibrillation. However, vitamin K antagonists remain standard due to unanswered questions about new drugs.

Area of Science:

  • Pharmacology
  • Internal Medicine
  • Cardiology

Background:

  • Vitamin K antagonists (VKAs) are established treatments for internal diseases.
  • Limitations in VKA pharmacokinetics and pharmacodynamics necessitate new anticoagulation therapies.
  • Direct thrombin inhibitors and factor Xa inhibitors represent targeted anticoagulation options.

Purpose of the Study:

  • To review the current situation regarding anticoagulation therapy.
  • To compare the efficacy and safety of new oral anticoagulants (NOACs) with VKAs.
  • To assess the role of NOACs in perioperative prophylaxis and long-term treatment.

Main Methods:

  • Review of clinical trial data for dabigatran etexilate, rivaroxaban, and apixaban.
  • Comparison of NOACs against low molecular weight heparins (LMWH) for prophylaxis.
  • Evaluation of NOACs versus VKAs for venous thrombosis treatment and atrial fibrillation stroke prophylaxis.

Main Results:

  • NOACs (dabigatran etexilate, rivaroxaban, apixaban) demonstrate effectiveness in perioperative venous thrombosis prophylaxis compared to LMWH.
  • Dabigatran etexilate shows comparable or superior efficacy to VKAs in long-term treatment of venous thrombosis and stroke prophylaxis for atrial fibrillation, with no increased safety concerns.
  • NOACs are under investigation for internal diseases.

Conclusions:

  • NOACs offer promising alternatives to VKAs, with proven efficacy and safety in specific indications.
  • VKAs will likely remain the standard oral anticoagulant until issues like therapy adherence and drug interactions with NOACs are fully resolved.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...